Tocilizumab for severe immune checkpoint inhibitor myopathy–myocarditis: acute and long-term outcomes
- 4 June 2026
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (6) , 368
Abstract
Background Immune checkpoint inhibitor (ICI)-myopathy–myocarditis is an immune-related adverse event, with high mortality despite first-line immunosuppression. Emerging data suggest upregulation of the interleukin-6 (IL-6) pathway in ICI-myopathy, raising interest in IL-6 receptor blockade as escalation therapy. We aimed to characterize acute and long-term functional and oncologic outcomes for severe ICI-myopathy–myocarditis, with focus on those treated with tocilizumab after failure of first-line therapy. Methods We performed a retrospective cohort study of patients admitted with severe (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or 4) ICI-myopathy–myocarditis managed at a Canadian tertiary referral center. Clinical characteristics, investigations, treatment, and functional and long-term cancer outcomes were summarized. Patients were stratified by treatment with tocilizumab after first-line therapy. Primary outcomes were in-hospital mortality and acute-phase survival. Secondary outcomes included functional status at last follow-up, final CTCAE grade, and oncologic response. Results Eleven patients were identified. Eight patients received second-line tocilizumab at a median of 13 days after admission; weakness improved in all, but only 4 survived hospitalization. Among acute-phase survivors, median follow-up was 8.1 months, with final median CTCAE grade of 1. Limb strength normalized before oculobulbar weakness. Most survivors demonstrated partial oncologic response, followed by later disease progression at a median 8 months. No patients were rechallenged with ICI therapy. Discussion In severe ICI-myopathy–myocarditis refractory to first-line therapy, escalation with IL-6 receptor blockade was temporally associated with limb muscle strength improvement and favorable long-term functional outcomes among survivors. These findings support further evaluation of tocilizumab as second-line therapy in this high-risk population.Keywords
This publication has 24 references indexed in Scilit:
- Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort studyThe Lancet Regional Health - Europe, 2025
- Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR studyAnnals of Oncology, 2024
- Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case seriesJournal of Neurology, 2023
- Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementEuropean Heart Journal, 2021
- Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case seriesEuropean Journal of Internal Medicine, 2021
- Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditisAnnals of Oncology, 2020
- Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathyBrain Communications, 2020
- THU0336 IMMUNE CHECKPOINT INHIBITOR-RELATED MYOSITIS: A RETROSPECTIVE COHORT STUDYAnnals of the Rheumatic Diseases, 2020
- Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated MyocarditisJournal of Thoracic Oncology, 2020
- Cancer immunotherapy using checkpoint blockadeScience, 2018